Federal Register Notice: FDA has determined the regulatory review period for Takeda Pharmaceutical’s Teflaro is 2,118 days for extending patents which claim the human drug product. Teflaro (ceftaroline fosamil) is indicated for treating the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections; and community-acquired bacterial pneumonia. To view this notice, click here.
